Financial Bioventus Inc. Reports Fourth Quarter and Full Year 2020 Financial Results; Introduces Full Year 2021 Financial Guidance byChris StewartMarch 26, 2021
Biologics Regulatory Bioventus Receives Authorization to Proceed Under Investigational New Drug Application for Clinical Trial of Placental Tissue Particulate (PTP-001) for the Treatment of Knee OA byChris StewartNovember 18, 2020
Biologics Bioventus Appoints Chris Yamamoto Senior Vice President of Business Development and Strategy byChris StewartNovember 16, 2020
Biologics Extremities Bioventus Reaches Milestone with 2 Million DUROLANE® Treatments Worldwide byChris StewartSeptember 22, 2020
Biologics Spine Bioventus Reports First Use of its SIGNAFUSE® Bioactive Bone Graft in Strip Format byJosh SandbergSeptember 2, 2020
Biologics Regulatory Bioventus Appoints Katrina Church Chief Compliance Officer byJosh SandbergAugust 24, 2020
Financial Bioventus Makes $15 Million Equity Investment in CartiHeal with an Agreed Option Structure to Acquire Company Upon Milestone Achievements byChris StewartJuly 16, 2020
Biologics Extremities Spine Bioventus Receives FDA Clearance of Strip Format of its SIGNAFUSE® Bioactive Bone Graft byJosh SandbergJune 25, 2020
Biologics Extremities Bioventus Selects Bazis NN as Distributor of DUROLANE® in Russia byChris StewartJune 15, 2020
Biologics Bioventus Recognizes 25 Years of Proven Bone Healing from EXOGEN byChris StewartFebruary 24, 2020
